Stock Scorecard
Stock Summary for ImmunityBio Inc (IBRX) - $5.16 as of 4/26/2024 7:39:46 AM EST
Total Score
2 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for IBRX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for IBRX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for IBRX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for IBRX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for IBRX
Financial Details for IBRX
Company Overview |
|
|---|---|
| Ticker | IBRX |
| Company Name | ImmunityBio Inc |
| Country | USA |
| Description | ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/9/2024 |
Stock Price History |
|
| Last Day Price | 5.16 |
| Last Day Price Updated | 4/26/2024 7:39:46 AM EST |
| Last Day Volume | 8,384,593 |
| Average Daily Volume | 5,528,950 |
| 52-Week High | 6.93 |
| 52-Week Low | 1.25 |
| Last Price to 52 Week Low | 312.80% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 61.03 |
| Sector PE | 61.73 |
| 5-Year Average PE | -6.22 |
| Free Cash Flow Ratio | 13.23 |
| Industry Free Cash Flow Ratio | 18.94 |
| Sector Free Cash Flow Ratio | 30.74 |
| Current Ratio Most Recent Quarter | 5.05 |
| Total Cash Per Share | 0.39 |
| Book Value Per Share Most Recent Quarter | -0.88 |
| Price to Book Ratio | 0.00 |
| Industry Price to Book Ratio | 7.50 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 5,561.87 |
| Industry Price to Sales Ratio Twelve Trailing Months | 9.51 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
| Total Shares Outstanding | 677,003,000 |
| Market Capitalization | 3,493,335,480 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -40.00% |
| Reported EPS 12 Trailing Months | -1.15 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -1.13 |
| Net Income Twelve Trailing Months | -583,196,000 |
| Net Income Past Year | -583,196,000 |
| Net Income Prior Year | -416,567,000 |
| Quarterly Revenue Growth YOY | 90.40% |
| 5-Year Revenue Growth | 67.62% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 266,462,000 |
| Total Cash Past Year | 266,462,000 |
| Total Cash Prior Year | 107,184,000 |
| Net Cash Position Most Recent Quarter | -570,490,000 |
| Net Cash Position Past Year | -570,490,000 |
| Long Term Debt Past Year | 836,952,000 |
| Long Term Debt Prior Year | 673,172,000 |
| Total Debt Most Recent Quarter | 836,952,000 |
| Equity to Debt Ratio Past Year | -2.35 |
| Equity to Debt Ratio Most Recent Quarter | -2.35 |
| Total Stockholder Equity Past Year | -586,987,000 |
| Total Stockholder Equity Prior Year | -447,327,000 |
| Total Stockholder Equity Most Recent Quarter | -586,987,000 |
Options |
|
| Put/Call Ratio | 1.24 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.02 |
| MACD Signal | 0.07 |
| 20-Day Bollinger Lower Band | 3.22 |
| 20-Day Bollinger Middle Band | 4.70 |
| 20-Day Bollinger Upper Band | 6.18 |
| Beta | 0.04 |
| RSI | 45.86 |
| 50-Day SMA | 3.33 |
| 200-Day SMA | 7.74 |
System |
|
| Modified | 4/25/2024 2:54:54 AM EST |